APAP

Global Analgesics Market Report 2023: Sector is Expected to Reach $67.4 Billion by 2028 at a CAGR of 4.49% - ResearchAndMarkets.com

Retrieved on: 
Monday, April 24, 2023
Health, Pharmaceutical, Organic acid, Oxycodone, Analgesic, USFDA, Pain, APAP, Morphine, Inflammation, Paracetamol, Consciousness, Nonsteroidal anti-inflammatory drug, Pharmaceutical industry

Analgesics are used for treating pain resulting from physiological injuries, surgeries, phantom aches, inflammation, neuropathic conditions and cancer treatments.

Key Points: 
  • Analgesics are used for treating pain resulting from physiological injuries, surgeries, phantom aches, inflammation, neuropathic conditions and cancer treatments.
  • However, by 2050, these numbers are expected to reach 2100 million, accounting for around 21% of the total global population.
  • The publisher provides an analysis of the key trends in each sub-segment of the global analgesics market report, along with forecasts at the global and regional level from 2023-2028.
  • Our report has categorized the market based on type, drug class, route of administration, pain type and application.

Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 30, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, APAP, Inc., Research, Vancomycin, Investment, COVID, Safety, Chair, Pharmaceutical industry, Video game, Cryptocurrency, Savara

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update.
  • Research and development expenses were $7.6 million for the fourth quarter of 2022, which were equivalent to the fourth quarter of 2021.
  • General and administrative expenses for the fourth quarter of 2022 and 2021 were $3.2 million and $3.0 million, respectively.
  • As of December 31, 2022, the Company had cash, cash equivalents and short-term investments of $125.9 million.

Savara Announces New Leadership Appointments

Retrieved on: 
Tuesday, February 14, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Inc., Marketing, Civil Service (United Kingdom), Chair, Finance, Lutz, Global Commercial Credit, Therapy, APAP, Rare, Management

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointments of two pharmaceutical industry veterans to its executive leadership team.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointments of two pharmaceutical industry veterans to its executive leadership team.
  • Rob Lutz has been appointed Chief Operating Officer, effectively immediately.
  • Scott Wilhoit was appointed Executive Vice President, Global Commercial, effective January 9, 2023, and Dave Lowrance was promoted from Chief Financial Officer to Chief Financial and Administrative Officer, effective December 13, 2022.
  • Our executive leadership team, strengthened by these new appointments, will continue to advance the molgramostim development program and begin planning to support its potential launch.”

"COME ON & GET IT", THE NEW ALBUM FROM VOCAL PROVOCATEUR JUDITH OWEN, CELEBRATES THE MUSIC OF THE "UNSUNG BADASS" LADIES OF JAZZ AND BLUES

Retrieved on: 
Tuesday, February 14, 2023
Glass, Brushy One String, Woman, Jamie Cullum, Come and Get Your Love, Toulouse, Orpheum Theater (New Orleans), Jelly Roll Morton, Singing, Music, TSF, Album, APAP, BBC Radio 2, New Orleans Jazz, Orpheum, DUC, Preservation Hall, Nice Jazz Festival, Salle Pleyel, Blue Note Records, Jazz, BBC, Snug Harbor, Night, Blue, Stolen Moments: The Lady Sings... Jazz and Blues, Winter Spring Summer Fall (album), Focus, Nightclub, New Orleans Jazz & Heritage Festival, COVID-19

NEW ORLEANS, Feb. 14, 2023 /PRNewswire/ -- Delicious, delightful, bodacious, brave, insightful, seductive and fun - just some of the many adjectives one might use to describe Judith Owen's fascinating and alluring new album, "Come On & Get It," releasing via London's Twanky Records.  The release of "Come On & Get It" is being accompanied by select tour dates worldwide including stops in London (the Omeira), Paris (Duc des Lombards) & TSF's You & The Night & The Music at Salle Pleyel - Paris, New York City (APAP), the New Orleans Jazz & Heritage Festival and more.   

Key Points: 
  • Early May will also see the release of a deluxe vinyl version of "Come On & Get It" (with two bonus tracks) and a deluxe digital version featuring five bonus tracks.
  • The release of the deluxe vinyl versions will coincide with Owen's highly-anticipated performance at the New Orleans Jazz & Heritage Festival on May 6th, as well as a comprehensive tour being planned for the US later this year.
  • Recorded at Esplanade Studios in New Orleans (where else could you hear such greasy joy that speaks of Storyville and Burlesque?
  • The new album has already gained  over 1 Million streams and more than 600,000 video views.

Savara Announces New Employment Inducement Grant

Retrieved on: 
Tuesday, November 22, 2022
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Inc., APAP, Employment, RSU, Degenerative disease, Granulocyte-macrophage colony-stimulating factor, Savara, Pulmonology, GM-CSF, Pharmaceutical industry

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of an employee inducement award.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of an employee inducement award.
  • The inducement award consists of options to purchase 375,000 shares of the Companys common stock and restricted stock units (RSUs) covering 150,000 shares of the Companys common stock.
  • This equity award was granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees acceptance of employment with the Company.
  • The RSUs vest in full on the two-year anniversary of the employees first day of employment, subject to the employees continued employment on such vesting date.

Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 10, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Review, Private Securities Litigation Reform Act, Forward-looking statement, Pulmonology, Chair, Investment, APAP, GM-CSF, SEC, Form, COVID, Inc., Company, Research, Granulocyte-macrophage colony-stimulating factor, Patient, CEO, Therapy, CMC, Contract research organization, Degenerative disease, COVID-19, Pharmaceutical industry, Chemistry, Savara

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2022 and provided a business update.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2022 and provided a business update.
  • I am delighted to join Savara as we advance the molgramostim development program, said Raymond Pratt, M.D., newly appointed Chief Medical Officer, Savara.
  • This was primarily attributable to a reduction of approximately $0.7 million in consulting activities during the three months ended September 30, 2022.
  • As of September 30, 2022, Savara had cash, cash equivalents, and short-term investments of approximately $134 million and debt of approximately $26 million.

Savara to Participate in Three Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 9, 2022
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Investor, GM-CSF, Granulocyte-macrophage colony-stimulating factor, Pulmonology, APAP, Inc., Savara, Degenerative disease, Pharmaceutical industry

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.

Key Points: 
  • Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.
  • Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
  • Molgramostim is delivered via an investigational eFlow Nebulizer System (PARI Pharma GmbH).
  • Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain

Retrieved on: 
Monday, September 26, 2022
Sciatic nerve, Adial, Virginia, GLOBE, Pain, APAP, RATS, Pressure, Chronic pain, Paracetamol, NASDAQ, Pharmaceutical industry

At 60 minutes post dose, PNV-5030 reduced pain by 76% compared to the control group (5.3g vs 1.8g, respectively, p

Key Points: 
  • At 60 minutes post dose, PNV-5030 reduced pain by 76% compared to the control group (5.3g vs 1.8g, respectively, p
  • This data further reinforces prior in vivo data demonstrating similar outcomes in treating other types of pain.
  • "PNV-5030 has demonstrated compelling data in animal models of both acute and chronic pain," said William Stilley, CEO of Purnovate.
  • The forward-looking statements include statements regarding Purnovates PNV-5030 as a potential treatment for chronic pain, namely PNV-5030s potential to significantly reduce pain compared to both placebo and acetaminophen.

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, September 14, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Employment, Pulmonology, Twitter, RSU, APAP, GM-CSF, Financial compensation, LinkedIn, Company, Inc., Degenerative disease, Board of directors, NASDAQ, Board, Nasdaq, Granulocyte-macrophage colony-stimulating factor, Pharmaceutical industry, Savara

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees.
  • On September 13, 2022, the Compensation Committee of Savara's Board of Directors granted inducement awards to three new employees who recently joined the Company.
  • These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees acceptance of employment with the Company.
  • The options have an exercise price of $1.46 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date.

Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022

Retrieved on: 
Tuesday, September 6, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, People, WLL, Fatigue, Fever, Article, Sex, Safety, Lipid, PAP, Degenerative disease, Chest (journal), Protein, Macrophage, Chronic cough, Exercise, Carbon monoxide, LinkedIn, GM-CSF, Granulocyte-macrophage colony-stimulating factor, APAP, ERJ, Antibody, Inc., Patient, Health status of Asian Americans, European Respiratory Journal, Respiratory tract infection, Pulmonary alveolar proteinosis, Twitter, Yolk sac, Congress, Clinical trial, Pulmonology, Common, Pharmaceutical industry, Vaccine, Medical imaging, Publication, Savara, IMPALA

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2022 that took place September 4-6th in Barcelona, Spain.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2022 that took place September 4-6th in Barcelona, Spain.
  • Additionally, patients reported improved health status, as measured by St. Georges Respiratory Questionnaire-Total and -Activity, when compared with placebo-treated patients .
  • Abstract #1154: Safety and Tolerability of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) presented by F. Bonella, M.D., Ph.D.
  • Additionally, the posters are scheduled to be published in a supplement of the European Respiratory Journal (ERJ) by the end of November 2022.